BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024
BiomX Inc. (NYSE American: PHGE), a clinical-stage company focused on natural and engineered phage therapies, has scheduled a conference call and webcast for November 14, 2024, at 8:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BiomX Inc. (NYSE American: PHGE), a clinical-stage company focused on natural and engineered phage therapies, has scheduled a conference call and webcast for November 14, 2024, at 8:00 a.m. ET. The event will cover the company's third quarter 2024 financial results, business updates, and program developments. Participants can join via phone at 1-877-407-0724 (U.S) or 1-201-389-0898 (International). The webcast will be accessible through the Investors section of BiomX's website.
Details
News Market Reaction – PHGE
The recorded move for PHGE in the trading session of this news was +4.63%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, November 14, 2024, at 8:00 a.m. ET, to report third quarter 2024 financial results and provide business and program updates.
To participate in the conference call, please dial 1-877-407-0724 (U.S) or 1-201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com.
About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.
BiomX, Inc.
Ben Cohen
benc@biomx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.